ATLASMoonLake Immunotherapeutics Class A (MLTX) earnings date: Nov 4, 2026
MoonLake Immunotherapeutics Class A (MLTX) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 4, 2026. Analysts expect EPS of -$0.77.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on MLTX
| Last price | $11.35 (-3.7%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.1% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 4 reports |
These figures come from the same calibrated model and valuation as the MoonLake Immunotherapeutics Class A stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
MoonLake Immunotherapeutics Class A reports on Nov 4, 2026. One email the day before, with ATLAS’s read on MoonLake Immunotherapeutics Class A. You can switch it off at any time.
Alert me before MLTX reportsFree to start. Creating an account takes under a minute.
Notify me when MoonLake Immunotherapeutics Class A reports
MLTX earnings at a glance
| Next report (confirmed) | Wed, Nov 4, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.77 |
| Last report | Aug 10, 2026 · Beat |
| Beat rate (last 4 reports) | 3 of 4 (75%) |
| Average EPS surprise | +5.1% |
| Average move around a report | ±5.5% (last 4) |
| Sector | Healthcare · Biotechnology |
MoonLake Immunotherapeutics Class A earnings history: last 4 reports
MoonLake Immunotherapeutics Class A last reported on Aug 10, 2026: EPS of -$0.84 against an estimate of -$0.90 (+6.7% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 10, 2026 | -$0.90 | -$0.84 | +6.7% | Beat | -9.2% |
| May 11, 2026 | -$0.92 | -$0.98 | -6.5% | Miss | +6.6% |
| Feb 25, 2026 | -$0.94 | -$0.92 | +2.1% | Beat | -2.9% |
| Feb 5, 2026 | $0.88 | $1.04 | +18.2% | Beat | +3.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for MLTX
See the fair value, the probability range and the earnings history of MoonLake Immunotherapeutics Class A on its ATLAS page.
MoonLake Immunotherapeutics Class A (MLTX) stock analysisPlans from €3.99 a month.
MoonLake Immunotherapeutics Class A earnings: frequently asked questions
When does MoonLake Immunotherapeutics Class A (MLTX) report earnings?
MoonLake Immunotherapeutics Class A is scheduled to report on Wednesday, November 4, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for MLTX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.77 per share (USD). Estimates can change before the report.
How often does MLTX beat earnings estimates?
Of its last 4 reports with a recorded result, MoonLake Immunotherapeutics Class A beat the EPS estimate 3 times; the average surprise was +5.1%. Past results do not predict the next one.
How much does MLTX move around earnings?
Over its last 4 reports the stock moved an average of 5.5% (absolute, from the close before the report day to the close after it), and finished higher 2 of 4 times.
Did MoonLake Immunotherapeutics Class A beat earnings estimates last quarter?
MoonLake Immunotherapeutics Class A last reported on Aug 10, 2026: EPS of -$0.84 against an estimate of -$0.90 (+6.7% surprise), a beat.
How much does MLTX usually move in a day?
On a normal trading day the ATLAS model puts MLTX’s one-day range at about ±4.1%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 4, 2026
Educational information, not investment advice. Disclaimer